Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06261060 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
A Phase 2 study of Familial Platelet Disorder and Hematopoietic, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06261060 is a Phase 2 study of Familial Platelet Disorder and Hematopoietic that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06261060, a Phase 2 study of Familial Platelet Disorder and Hematopoietic, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.
Conditions Studied
Interventions
- DRUG Sirolimus
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2028-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06261060
The ClinicalTrials.gov registry entry for NCT06261060 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Familial Platelet Disorder appearing as the primary indexed condition, and to 1 intervention - of which Sirolimus is the first listed.
NCT06261060 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06261060 about?
NCT06261060 is a clinical study titled "Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder". To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.
What is the current status of trial NCT06261060?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2024-06-20. Estimated completion is 2028-06-11.
What conditions does trial NCT06261060 study?
This clinical trial studies the following conditions: Familial Platelet Disorder, Hematopoietic.
What interventions are being tested in trial NCT06261060?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT06261060?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06261060 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.